Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial-Reference-Cited by-同舟云学术

Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial

Published:2022-08 Issue:8 Volume:23 Page:1044-1054
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Pautier Patricia,Italiano Antoine,Piperno-Neumann Sophie,Chevreau Christine,Penel Nicolas,Firmin Nelly,Boudou-Rouquette Pascaline,Bertucci François,Balleyguier Corinne,Lebrun-Ly Valérie,Ray-Coquard Isabelle,Kalbacher Elsa,Bardet Aurélie,Bompas Emmanuelle,Collard Olivier,Isambert Nicolas,Guillemet Cécile,Rios Maria,Archambaud Baptiste,Duffaud Florence,ITALIANO Antoine,PAUTIER Patricia,LECESNE Axel,PIPERNO-NEUMANN Sophie,CHEVREAU Christine,CUPISSOL Didier,PENEL Nicolas,ALEXANDRE Jérôme,BERTUCCI François,RAY-COQUARD Isabelle,LEBRUN-LY Valérie,KALBACHER Elsa,DUFFAUD Florence,DELCAMBRE Corinne,BOMPAS Emmanuelle,COLLARD Olivier,ISAMBERT Nicolas,GUILLEMET Cécile,SOULIE Patrick,RIOS Maria,SAADA-BOUZID Esma

Funder

Merck

Roche

Publisher

Elsevier BV

Subject

Oncology

Reference29 articles.

1. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing;Ducimetière;PLoS One,2011

2. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial;Judson;Lancet Oncol,2014

3. Randomized Phase III Study Comparing Conventional-Dose Doxorubicin Plus Ifosfamide Versus High-Dose Doxorubicin Plus Ifosfamide Plus Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Advanced Soft Tissue Sarcomas: A Trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group

4. Differential gene expression in leiomyosarcoma;Skubitz;Cancer,2003

5. Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first‐line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diphenyl Diselenide Through Reduction of Inflammation, Oxidative Injury and Caspase-3 Activation Abates Doxorubicin-Induced Neurotoxicity in Rats;Neurochemical Research;2024-01-24

2. When Vessels and Sarcomas Combine: A Review of the Inferior Vena Cava Leiomyosarcoma;Journal of Vascular Diseases;2024-01-08

3. Beneficial Use of the Combination of Gemcitabine and Dacarbazine in Advanced Soft Tissue Sarcomas: Real-World Data;Cancers;2024-01-08

4. Unresectable leiomyosarcoma of the inferior vena cava with right atrium tumor thrombus: when to deem this tumor inoperable? A case report and literature review;Frontiers in Oncology;2024-01-04

5. Trabectedin and low-dose radiation therapy in patients with advanced leiomyosarcoma;Therapeutic Advances in Medical Oncology;2024-01